JSPR · Jasper Therapeutics, Inc. · Analyst Estimates
$0.66
-0.04 (-5.77%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, based on the Company's current operating plan, and along with the Company's history of operating losses, and given the potential risk of having to repurchase the Non-Voting Convertible Preferred Stock if the Company is unable to obtain stockholder approval to convert it to Common Stock within 12 months, the Company's current cash and cash equivalents may not be sufficient to fund the Company's ongoing operations for a period of at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$21.97M
Shares
33.27M
Analyst Estimates
Compare analyst forecasts for Jasper Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Only independently verified consensus published through the company's investor-relations sources is available.
Consensus not yet available
Only independently verified consensus published through the company's investor-relations sources is available.
Key facts
CIK
1788028
CUSIP
471871202
13F (30d)
24 filings
24 filers
Visit website
Investor relations